HYBRIGENICS France

HYBRIGENICS Hybrigenics is a biopharmaceutical company involved in the discovery and the development of new anticancer drugs. Industry sectors Biotech Therapeutics Area Oncology
Your innovative solution

Hybrigenics is developing inecalcitol, a vitamin D receptor agonist, characterized by enhanced activities against cancer cell proliferation and much reduced toxicity on blood calcium levels as compared to calcitriol, the active form of vitamin D. Therefore, inecalcitol can be given at high daily oral doses which exert cytostatic effects on tumors. 

Which problem are you solving ?

Acute myeloid leukemia (AML) has the worse prognosis of all types of leukemias (<25% 5-year survival). Furthermore, elderly or frail AML patients cannot support standard induction chemotherapy and are eligible only to treatment with either decitabine or azacytidine, two hypo-methylating agents. The goal is to increase overall survival of these desperate patients by adding daily oral inecalcitol to hypo-methylating therapy.

Target market segments

Pharmaceutical products / anticancer agents / hematological malignancies / small chemical drugs /

Key value proposition

Orphan drug status already granted for AML in US and EU / Excellent tolerance in patients / convenient daily oral dosing favoring compliance / Strong proof of principle in animal AML models

Rémi DELANSORNE
CEO 

I Sonic Medical France

i Sonic Medical Makers of Next Generation non Contact Tonometers for glaucoma monitoring Industry sectors Medtech Therapeutics Area Ophthalmology
Your innovative solution

Vibration tonometry enables smart tonometers to measure eye pressure without contact,for ophthalmologists, refractive surgeons , otpicians and optometrists and self monitoring at home.

Which problem are you solving ?

Vibration tonometers measure eye pressure independently of corneal thickness and even in people with thin corneas or after refractive surgery

Target market segments

1 Ophthalmologists/ 2 Refractive Surgeons/ 3 opticians & Optometrists/ 4 people with glaucoma or at risk

Key value proposition

1 Fast Repeated measures/ 2 Works on Thin Cornea/3 Measures Corneal elasticity/4 Works after refrtactive surgery

Website:
NULL
Pierre BITOUN
NULL 

i2a France

i2a Founded over 25 years ago, i2a develops microbiology instruments, software, reagents and consumables. i2a is now launching a Total Bacteriology Lab Automation solution. Industry sectors Medtech Therapeutics Area Immunology
Infectious Diseases - Vaccines
Ivd / Diagnostics
Your innovative solution

i2a is a company working on microbiology automation. The objective is to offer a global solution from the arrival of samples to the final results. i2a manufactures and sells pre-analytical device, automatic incubator automatic reader-incubator, software, reagents and consumables. The current total bacteriology automation proposed by i2a strengthens quality, optimizes sample flow, enhances flexibility and reduces costs.

Which problem are you solving ?

Each clinical microbiology laboratory is unique and its organization may vary, but they all have seen a 10 

Target market segments

Market segment 1: Hospital Clinical Lab of Microbiology Market segment 2: Reference Lab of Microbiology Market segment 3: Small and Medium Private Lab of Microbiology

Key value proposition

Advantage 1: Strenghten quality Advantage 2: Enhance flexibility Advantage 3: Optimize sample flow Advantage 4: Reduce costs

Christian Curel
CEO & Founder 

Indigo therapeutics France

Indigo therapeutics & Gynov
  • Indigo designs, manufactures and supplies innovative dietary supplements focused on gastrointestinal tract (GIT) pathologies and conditions or deficiencies requiring specific clinical nutrition
  • Gynov, Indigo's sister company, applies the same rules of design and manufacturing for gynecological / obstetrics sphere
Therapeutics Area
  • Gastroenterology / Hepatology
  • Immunology
  • Infectious Diseases - Vaccines
  • Nutrition and Weight Loss
  • Obstetrics/Gynecology (Women's Health)
Our innovative solutions

Besides opportunistic developments, our R&D aims at producing new generation probiotics / synbiotics combining a selection of relevant strains in relation to the progresses on microbiota, a microencapsulation technology promoting the survival and the production of molecules of interest, and a pharmaceutical macro-encapsulation vectorizing active ingredients to the therapeutic target

Problems we address

Indigo addresses medical problems or conditions which currently lack of efficient or well-tolerated solutions. Besides, Indigo provides a clear rational while exploiting the potential of probiotics / synbiotics still faces some uncertainty among healthcare professionals.

Gynov addresses obstetrical issues for which currently available medications are contra-indicated. Thus, Gynov conceives specialized dietary supplements based upon high-quality GRAS ingredients that have demonstrated their efficacy for Gyn/Obst issues

Target market segments
  • Irritable bowel disease (IBD)
  • Prevention & treatment of diarrheas
  • Dialysis for end-stage renal failure
  • Fertility & obstetrics
Key values
  • Robust medico-scientific background
  • High manufacturing & product quality (GMP)
  • Exclusive promotion towards medical doctors
  • High value academic partnerships
Pierre-Yves MOUSSET
CEO 

Inferential France

Inferential  Biostatistical expertise and services for all types of studies Industry sectors Other: Biostatistics Therapeutics Area Cardiology / Vascular Diseases
CNS-Neurology
Dental and Oral Health
Dermatology
Endocrinology
Gastroenterology / Hepatology
Immunology
Infectious Diseases - Vaccines
Ivd / Diagnostics
Nutrition and Weight Loss
Obstetrics/Gynecology (Women's Health)
Oncology
Ophthalmology
Orthopedics/Orthopedic Surgery
Otolaryngology (Ear, Nose, Throat)
Pulmonary/Respiratory Diseases
Rare Disease
Psychiatry/Psychology
Rheumatology
Your innovative solution

Inferential provides statistical expertise and delivers results and statistical reports for any type of study incl clinical, NIS, health-economics, epidemiology

Which problem are you solving ?

While health authorities are more and more demanding in terms of data quality and study standards, most pharmaceutical companies own less and less skilled statistical resources. Inferential acts as the client's own statistical department or an extension thereof.

Target market segments

1)Pharmaceutical companies 2)Biotechs 3) Device 4) Cosmetics and nutrition 5) Vet

Key value proposition

1) Hign expertise with low overhead costs 2) Broad experience in both US and EMEA regulatory context

Anne HUMMLER
CEO 

Intellitech France

Intellitech Robust Predictive Modeling of Complex Processes based on an Intelligent Analysis of Big / Smart Data Industry sectors Other: Predictive Me Therapeutics Area Cardiology / Vascular Diseases
CNS-Neurology
Dental and Oral Health
Dermatology
Endocrinology
Gastroenterology / Hepatology
Immunology
Infectious Diseases - Vaccines
Ivd / Diagnostics
Nutrition and Weight Loss
Obstetrics/Gynecology (Women's Health)
Oncology
Ophthalmology
Orthopedics/Orthopedic Surgery
Otolaryngology (Ear, Nose, Throat)
Pediatrics/Neonatology
Pulmonary/Respiratory Diseases
Rare Disease
Psychiatry/Psychology
Rheumatology
Your innovative solution

Our xtractis' robot incorporates the latest advances in Artificial Intelligence, especially Fuzzy Logic and Machine Learning. It analyses a multidimensional database and automatically discovers robust fuzzy rule-based Decision Support Systems which are able to predict with the most reliability the complex process under study.

Which problem are you solving ?

Robust Predictive Models for Epigenetics Personalized Medicine and Pharmacogenomics: Drug Discovery (efficiency, toxicity), Early Diagnosis, Companion Diagnostic, Virtual Screening, Selection of Best Target Patients, Disease Evolution, Survival Duration, Preventive Care, Environmental/Life-style/Diet/Therapeutic Recommendations, Side Effects & Adverse Events, Protein Homology, Reimbursement Rate of a Drug, Insurance Risk Scoring of a Patient

Target market segments

Pharmaceutical Industry / Personalized Medicine Diagnostics / Hospitals & Medical Centers / Private or Public Insurers

Key value proposition

Unique mathematical approach (fuzzy, possibilistic, inductive, automatic, holistic, non-linear, non-monotonic, without a priori) / Proprietary algorithms implemented in fully automated software with user-friendly MMI / Better predictive capacity (robustness) vs. prevailing world-class techniques / Handles weak signals and low quality data

Website:
www.xtractis.com
Prof. Zyed ZALILA
President and CEO 

MEDIAN Technologies France

MEDIAN Technologies MEDIAN Technologies provides advanced software solutions, medical expertise and services for interpretation and management of images in oncology. Industry sectors Medtech Therapeutics Area Oncology
Your innovative solution

Our technology helps automate/standardize image interpretation ; it also enables quantification of standard imaging criteria and advanced imaging biomarkers, to provide early proof of treatment response. Our Lesion Management Solutions (LMS) platform is a proprietary suite of software modules for automated/semi-automated detection, quantitative measurement and follow-up of tumors. 

Which problem are you solving ?

MEDIAN's technology solves frequently observed issues in image interpretation such as intra- and inter-reader variability of measurement or lack of standardization of reading/interpretation processes. Both variability and insufficient level of standardization lead to a decrease of imaging data reliability, which can, for instance impact the statistical power of data in clinical trials. 

Target market segments

Oncology drug development -clinical trials (phases I to phases III) / Novel biomarkers development in oncology and other therapeutic areas / Imaging based cancer screening programs

Key value proposition

Quantitative and standardized data analysis supported by cutting edge, FDA approved, technology / Expertise in advanced imaging biomarkers for more accurate evaluation of drug efficacy / Real time, streamlined image workflow for clinical trials

Jerome WINDSOR
VP Business development 

MEDICEN France

Are you seeking to develop your R&D skills, enhance your innovation potential and increase your business opportunities ? Check how Medicen Paris Region can help you.

Ms Béatrice Falise-Mirat
CEO 

Medissimo France

Medissimo Medissimo offers tools for preparation of prebscription (pillboxes) with full traceability Industry sectors Other: Health and tr Therapeutics Area Adherence
Your innovative solution

imedipac is a connceted, rec hageable, pillbox for better treatment adhrence

Which problem are you solving ?

imedipac's main objective is to increase treatment adherence and measure it 

Target market segments

Patients at home/patients in nursing homes

Key value proposition

Well designed connected pillbox/reliability/total traceability/very good knowledge of our market in France

Caroline Blochet
Presidente 

MIDI CAPITAL France

 

 

 

Midi Capital is a rapidly growing independent private equity company, specialized in financing small and medium businesses.
Midi Capital manages over € 260 million and a portfolio of investments of 120 small and medium companies covering a wide range of industrial and service sectors (Medical & Life Science, Digital & media, Brands & Retail) .

In 6 métropoles (Barcelone, Lyon, Paris, Toulouse, Marseille, Nice) our teams (40 people) work with a wide range of entrepreneurs and company cultures. But we all share a common ambition: help our entrepreneurs to be and remain the leaders they want to be, to lead the change.
small and medium businesses.

   
Jean Baptiste FREY
Investment Manager